Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
1(10%)
Results Posted
100%(6 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
6
60%
Ph phase_3
2
20%
Ph phase_4
2
20%

Phase Distribution

0

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)
Other(1)

Detailed Status

Completed6
Recruiting1
Terminated1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (60.0%)
Phase 32 (20.0%)
Phase 42 (20.0%)

Trials by Status

recruiting110%
terminated110%
completed660%
unknown110%
withdrawn110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT04226950Phase 2

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Recruiting
NCT05395507Phase 2

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Unknown
NCT01710501Phase 2

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Completed
NCT03547154Phase 2

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Terminated
NCT02155322Phase 2

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Completed
NCT00686777Phase 4

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Completed
NCT00686517Phase 3

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Completed
NCT02168361Phase 4

The SIM-SOF Trial for Hepatitis C

Completed
NCT01871662Phase 2

Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C

Withdrawn
NCT00230958Phase 3

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10